Shared on 27 Aug 25

Fair value Increased 4.20%

Beam Therapeutics’ consensus price target has increased to $45.92, reflecting notable improvements in net profit margin and a lower future P/E, signaling enhanced profitability and a more attractive valuation. What's in the News BEAM-101 for sickle cell disease received FDA RMAT and orphan drug designations; updated Phase 1/2 BEACON data show strong, durable increases in fetal hemoglobin, with sustained safety and efficacy for 17 treated patients.

Read more

0 votesShare

Shared on 01 May 25

Fair value Decreased 9.39%

Read more

0 votesShare

Shared on 24 Apr 25

Fair value Increased 10%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 17 Apr 25

Fair value Decreased 9.40%

Read more

0 votesShare

Shared on 09 Apr 25

Fair value Increased 18%

AnalystConsensusTarget has increased future PE multiple from 397.2x to 472.3x.

Read more

0 votesShare

Shared on 02 Apr 25

Fair value Decreased 17%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 26 Mar 25

Fair value Increased 12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare